US Firm to Trial Bird Flu Vaccine in Indonesia, Hong Kong (Indonesia)
This article was originally published in PharmAsia News
U.S.-based Baxter Healthcare will conduct clinical trials beginning in July 2007 in Singapore and Hong Kong to develop an avian flu vaccine. The trials will use an avian flu viral strain from Indonesia. Baxter has an agreement with the Indonesian government to deliver a human bird flu vaccine to that country. Indonesia plans to purchase or produce around 20 million vaccine doses, enough to inoculate 10 percent of the population during a pandemic, said Indonesian Health Minister Siti Fadilah Supari. (Click here for more
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.